Serial increase of IL-12 response and human leukocyte antigen-DR expression in severe sepsis survivors

Critical Care

Volumn 15, Issue 5, 2011, Pages

  Wu, Huang Pin ^a,b   Shih, Chi Chung ^a,b   Lin, Chun Yao ^a   Hua, Chung Ching ^a   Chuang, Duen Yau ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Human leukocyte antigen DR; Interleukin 12; Interleukin 6; Peripheral blood mononuclear cells; Severe sepsis

Indexed keywords

HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MONOCYTE; OBSERVATIONAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SEPSIS; SURVIVOR; BLOOD; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; MORTALITY; TIME;

AGED; BIOLOGICAL MARKERS; FEMALE; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MALE; PROSPECTIVE STUDIES; SEPSIS; SURVIVORS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054968884     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10464     Document Type: Article

References (29)

1. Reddy RC, Chen GH, Tekchandani PK, Standiford TJ. Sepsis-induced immunosuppression: from bad to worse. Immunol Res 2001, 24:273-287. 10.1385/IR:24:3:273, 11817325.
2. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
3. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14:64-78. 2078557, 18026569.
4. Perry SE, Mostafa SM, Wenstone R, Shenkin A, McLaughlin PJ. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?. Intensive Care Med 2003, 29:1245-1252. 10.1007/s00134-003-1686-2, 12774155.
5. Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002, 166:1475-1482. 10.1164/rccm.200203-217OC, 12406851.
6. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000, 117:1162-1172. 10.1378/chest.117.4.1162, 10767254.
7. Wu HP, Chen CK, Chung K, Jiang BY, Yu TJ, Chuang DY. Plasma transforming growth factor-β1 level in patients with severe community-acquired pneumonia and association with disease severity. J Formos Med Assoc 2009, 108:20-27. 10.1016/S0929-6646(09)60028-0, 19181604.
8. Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 2004, 11:161-167. 321326, 14715564.
9. Stanilova SA, Karakolev ZT, Dimov GS, Dobreva ZG, Miteva LD, Slavov ES, Stefanov CS, Stanilov NS. High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors. Intensive Care Med 2005, 31:401-407. 10.1007/s00134-005-2575-7, 15719148.
10. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007, 11:R49. 10.1186/cc5783, 2206478, 17448250.
11. Wu HP, Chen CK, Chung K, Tseng JC, Hua CC, Liu YC, Chuang DY, Yang CH. Serial cytokine levels in patients with severe sepsis. Inflamm Res 2009,
12. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476. 10.1016/j.immuni.2004.08.018, 15485625.
13. Russell JA. Management of sepsis. N Engl J Med 2006, 355:1699-1713. 10.1056/NEJMra043632, 17050894.
14. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256. 10.1097/01.CCM.0000050454.01978.3B, 12682500.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
16. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, . Surviving Sepsis Campaign Management Guidelines Committee Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873. 10.1097/01.CCM.0000117317.18092.E4, 15090974, Surviving Sepsis Campaign Management Guidelines Committee.
17. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, , , , , , , . International Surviving Sepsis Campaign Guidelines Committee, American Association of Critical-Care Nurses, American College of Chest Physicians, American College of Emergency Physicians, Canadian Critical Care Society, European Society of Clinical Microbiology and Infectious Diseases, European Society of Intensive Care Medicine; European Respiratory Society, International Sepsis Forum, Japanese Association for Acute Medicine, Japanese Society of Intensive Care Medicine, Society of Critical Care Medicine, Society of Hospital Medicine, Surgical Infection Society, World Federation of Societies of Intensive and Critical Care Medicine Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437, International Surviving Sepsis Campaign Guidelines Committee, American Association of Critical-Care Nurses, American College of Chest Physicians, American College of Emergency Physicians, Canadian Critical Care Society, European Society of Clinical Microbiology and Infectious Diseases, European Society of Intensive Care Medicine; European Respiratory Society, International Sepsis Forum, Japanese Association for Acute Medicine, Japanese Society of Intensive Care Medicine, Society of Critical Care Medicine, Society of Hospital Medicine, Surgical Infection Society, World Federation of Societies of Intensive and Critical Care Medicine.
18. Monneret G, Finck ME, Venet F, Debard AL, Bohe J, Bienvenu J, Lepape A. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 2004, 95:193-198. 10.1016/j.imlet.2004.07.009, 15388260.
19. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005, 174:5110-5118.
20. Lukaszewicz AC, Grienay M, Resche-Rigon M, Pirracchio R, Faivre V, Boval B, Payen D. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009, 37:2746-2752. 10.1097/CCM.0b013e3181ab858a, 19707128.
21. Hynninen M, Pettilä V, Takkunen O, Orko R, Jansson SE, Kuusela P, Renkonen R, Valtonen M. Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock 2003, 20:1-4. 10.1097/01.shk.0000068322.08268.b4, 12813360.
22. Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard AL, Thizy H, Bienvenu J, Gueyffier F, Vanhems P. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006, 32:1175-1183. 10.1007/s00134-006-0204-8, 16741700.
23. Weighardt H, Heidecke CD, Westerholt A, Emmanuilidis K, Maier S, Veit M, Gerauer K, Matevossian E, Ulm K, Siewert JR, Holzmann B. Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann Surg 2002, 235:560-567. 10.1097/00000658-200204000-00015, 1422472, 11923613.
24. Ozbalkan Z, Aslar AK, Yildiz Y, Aksaray S. Investigation of the course of proinflammatory and anti-inflammatory cytokines after burn sepsis. Int J Clin Pract 2004, 58:125-129. 10.1111/j.1368-5031.2004.0106.x, 15055859.
25. Selberg O, Hecker H, Martin M, Klos A, Bautsch W, Kohl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med 2000, 28:2793-2798. 10.1097/00003246-200008000-00019, 10966252.
26. White M, Lawless MW, O'Dwyer MJ, Grealy R, Connell BO, Stordeur P, Kelleher D, McManus R, Ryan T. Transforming growth factor β-1 and interleukin-17 gene transcription in peripheral blood mononuclear cells and the human response to infection. Cytokine 2010, 50:322-327. 10.1016/j.cyto.2010.01.003, 20207161.
27. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898. 10.1056/NEJMra0707449, 19710487.
28. Fisher CJ, Dhainaut JFA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC, Astiz M, Carpati C, Balk RA, Bone RC, Friedman B, Mure AJ, Brathwaite C, Shapiro E, Melhorn L, Taylor R, Keegan M, O'Brien J, Schein R, et al. The Phase III rhIL-1ra Sepsis Syndrome Study Group Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994, 271:1836-1843. 10.1001/jama.271.23.1836, 8196140, The Phase III rhIL-1ra Sepsis Syndrome Study Group.
29. Macias WL, Nelson DR, Williams M, Garg R, Janes J, Sashegyi A. Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. Crit Care 2005, 9:R607-R622. 10.1186/cc3795, 1414006, 16280057.